Original Article
Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma

Wen-Yu Chuang, Yu-Sun Chang, Yin-Kai Chao, Chi-Ju Yeh, Shir-Hwa Ueng, Chiu-Yueh Chang, Yun-Hen Liu, Chen-Kan Tseng, Hsien-Kun Chang, Yung-Liang Wan, Chuen Hsueh

1Department of Pathology, 2Chang Gung Molecular Medicine Research Center and Graduate Institute of Basic Medical Sciences, 3Division of Thoracic and Cardiovascular Surgery, Department of Surgery, 4Department of Radiation Oncology, 5Division of Hematology and Oncology, Department of Internal Medicine, 6Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan

Received July 14, 2015; Accepted August 23, 2015; Epub October 1, 2015; Published October 15, 2015

Abstract: Mechanistic (or mammalian) target of rapamycin (mTOR) plays important roles in cell growth and proliferation. In esophageal squamous cell carcinoma (SCC), high expression of phosphorylated (activated) mTOR (p-mTOR) has been reported as an adverse prognostic factor in some but not all studies. The signals of mTOR pathway and mitogen-activated protein kinase (MAPK) pathway converge on 4E-binding protein 1 (4EBP1), which drives the downstream proliferative signals. We previously found that high expression of phosphorylated 4EBP1 (p-4EBP1) is an adverse prognostic factor in esophageal SCC. Podoplanin is a type-1 transmembrane glycoprotein expressed in various normal human tissues, including lymphatic endothelium. Our previous study showed that high podoplanin expression correlates with clinical nodal metastasis, which is associated with short survival in esophageal SCC. In current study, we investigated p-mTOR expression by immunohistochemistry in 75 cases of surgically resected esophageal SCC. The result was correlated with p-4EBP1 expression, podoplanin expression, clinicopathologic features and patient survival. We found that high p-mTOR expression was significantly associated with high podoplanin expression \( (P = 0.0030) \) and high tumor grade \( (P = 0.0014) \). No correlation with p-4EBP1 expression, patient survival or other clinicopathologic features was found. Recently, podoplanin expression in astrocytic brain tumors was found to be regulated by the phosphatidylinositol 3-kinase (PI3K)/AKT/activator protein-1 (AP-1) pathway. Similarly, mTOR is activated by a PI3K/AKT/mTOR pathway. The association of p-mTOR and podoplanin expression in our study could be due to a common upstream pathway. Since both mTOR and podoplanin are potential therapeutic targets, the possible benefit of combined targeted therapy warrants further investigation.

Keywords: Mechanistic target of rapamycin (mTOR), podoplanin, 4E-binding protein 1 (4EBP1), tumor grade, esophagus, squamous cell carcinoma

Introduction
Esophageal squamous cell carcinoma (SCC) is a highly aggressive cancer [1]. More than 50% of the patients present with unresectable or metastatic disease. Despite the development of multimodality treatment including surgery, chemotherapy and radiotherapy, the overall five year survival rate remains to be 10-20% [1]. Further understanding of molecular pathways is needed to identify therapeutic targets and improve patient survival.

Mechanistic (or mammalian) target of rapamycin (mTOR) is a serine/threonine kinase which regulates cell growth, proliferation and metabolism [2-5]. It is activated by phosphorylation of Ser2448 through the phosphatidylinositol 3-kinase (PI3K)/AKT/activator protein-1 (AP-1) pathway. Similarly, mTOR is activated by a PI3K/AKT/mTOR pathway. The association of p-mTOR and podoplanin expression in our study could be due to a common upstream pathway. Since both mTOR and podoplanin are potential therapeutic targets, the possible benefit of combined targeted therapy warrants further investigation.
has been reported to influence survival in two studies [10, 11] but does not in one [12].

The signals of mTOR pathway and mitogen-activated protein kinase (MAPK) pathway converge on 4E-binding protein 1 (4EBP1), which drives the downstream proliferative signals [13]. Previously, we found that high expression of phosphorylated 4EBP1 (p-4EBP1) was an independent adverse prognostic factor in esophageal SCC patients [14, 15].

Podoplanin is a type 1 transmembrane mucin-like glycoprotein. It is expressed by a variety of normal human tissues, including lymphatic endothelial cells, glomerular podocytes, heart, lung, placenta, skeletal muscle, myofibroblasts, myoepithelial cells, mesothelial cells, osteoblasts, follicular dendritic cells, Schwann cells, and the basal layer of epidermis and esophageal mucosa [16-24]. The physiological functions and pathways of podoplanin are largely unknown and probably involved in regulation of lymphangiogenesis and renal glomerular filtration [25, 26].

Podoplanin is variably expressed in SCC of esophagus, oral cavity, larynx, uterine cervix and skin [23, 27-29]. It has been demonstrated to play a role in lymphangiogenesis, nodal metastasis [30], carcinogenesis [31, 32], cell motility, tumor invasiveness [27], platelet aggregation and hematogenous metastasis [33]. High podoplanin expression in tumor cells has been found to correlate with nodal metastasis and poor prognosis in esophageal SCC by our group and later by others [23, 34-36].

Podoplanin expression in astrocytic brain tumors was found to be regulated by the PI3K/AKT/activator protein-1 (AP-1) pathway [37], thus it shares a common upstream pathway with mTOR. In addition, the activated mTOR signal through PI3K/AKT/mTOR pathway converges on 4EBP1 [13]. It would be of interest to see whether there is any correlation between mTOR
p-mTOR in esophageal cancer

expression and the expression of podoplanin and p-4EBP1. Therefore, we investigated p-mTOR expression in 75 surgically resected esophageal SCC by immunohistochemistry. The result was correlated with p-4EBP1 expression, podoplanin expression, clinicopathologic features and patient survival.

Materials and methods

Patients

A total of 75 cases of surgically resected esophageal SCC were recruited for this study. Fifty-four of the patients received pre-operative concurrent chemoradiotherapy (CCRT). Pathologic and pre-operative clinical staging was performed according to the 7th edition AJCC Cancer Staging Manual [38].

Immunohistochemistry

Resected esophageal SCC and adjacent normal tissue were fixed in 10% buffered neutral formalin, dehydrated and embedded in paraffin. Tissue sections were routinely stained for hematoxylin and eosin for morphologic evaluation. Additional 4-µm-thick sections were taken, deparaffinized and rehydrated for immunohistochemical study. We used a monoclonal rabbit anti-p-mTOR antibody (clone EPR426 (2), Epitomics, Burlingame, CA, USA, 1:100) as the primary antibody. Antigen retrieval was performed with EDTA pH 9.0 buffer (Leica). Sections were incubated with primary antibody at 4°C overnight, followed with poly-horseradish peroxidase (HRP) antimouse/rabbit IgG reagent (Zymed) to localize the primary antibody, and dianaminobenzidine (DAB) was used to visualize the complex. Then the sections were counterstained with hematoxylin, dehydrated, cleared, and mounted.

The immunostained slides were evaluated by two pathologists (W-Y. C. and C-J. Y.) under a dual-head microscope without knowing the clinicopathologic information. A H-score (H-score; range = 0-300) was calculated by multiplying the intensity score (0 = negative; 1 = weak; 2 = intermediate; 3 = strong; Figure 1) and the fraction score (percentage of positive tumor cells; range = 0-100). When areas of different intensity were present in one sample, the H-score of each intensity area was calculated separately and the sum of all H-scores was regarded as the final H-score.

These cases were also investigated for tumor cell expression of p-4EBP1 and podoplanin as previously described [14, 23]. Some of these results have been reported in our previous studies [14, 23].

Statistical analysis

Differences in categorical data were assessed by a chi-square test, and Yates' correction was performed if expected frequencies less than 5 were encountered. Difference in age or H-score between groups was assessed by Mann-Whitney U-test. Overall survival was analyzed by Kaplan-Meier method and compared by log-rank tests. P value < 0.05 was considered statistically significant. All statistical analyses were done using the WinSTAT® for Excel (R. Fitch Software, Bad Krozingen, Germany).

Results

P-mTOR expression and clinicopathologic characteristics

The H-scores of p-mTOR immunostaining ranged from 1 to 165, with a median of 80. An H-score of 80 or more was considered high p-mTOR expression (n = 39), whereas an H-score of 79 or lower was considered low expression (n = 36). Expression of p-mTOR had no significant influence on patient survival (P = 0.45; Figure 2). The clinicopathologic characteristics grouped by p-mTOR expression were listed in Table 1. Of note, high p-mTOR expression was strongly associated with high tumor grade (grade 3; P = 0.0014). We found no cor-
p-mTOR in esophageal cancer

Table 1. Clinicopathologic characteristics of cases grouped by p-mTOR expression

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>p-mTOR expression</th>
<th>Total (n = 75)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (n = 36)</td>
<td>High (n = 39)</td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>59 ± 13</td>
<td>56 ± 11</td>
<td>57 ± 12</td>
</tr>
<tr>
<td>Median (min; max)</td>
<td>58 (38; 100)</td>
<td>58 (32; 85)</td>
<td>58 (32; 100)</td>
</tr>
<tr>
<td>Gender (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>2 (6)</td>
<td>1 (3)</td>
<td>3 (4)</td>
</tr>
<tr>
<td>Male</td>
<td>34 (94)</td>
<td>38 (97)</td>
<td>72 (96)</td>
</tr>
<tr>
<td>Pre-operative CCRT (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>22 (61)</td>
<td>29 (74)</td>
<td>51 (68)</td>
</tr>
<tr>
<td>No</td>
<td>14 (39)</td>
<td>10 (26)</td>
<td>24 (32)</td>
</tr>
<tr>
<td>Tumor grade (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1-2</td>
<td>34 (94)</td>
<td>25 (64)</td>
<td>59 (79)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>2 (6)</td>
<td>14 (36)</td>
<td>16 (21)</td>
</tr>
<tr>
<td>pT (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT1-2</td>
<td>10 (28)</td>
<td>15 (38)</td>
<td>25 (33)</td>
</tr>
<tr>
<td>pT3-4</td>
<td>26 (72)</td>
<td>24 (62)</td>
<td>50 (67)</td>
</tr>
<tr>
<td>pN (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pN0</td>
<td>21 (58)</td>
<td>24 (62)</td>
<td>45 (60)</td>
</tr>
<tr>
<td>pN1-3</td>
<td>15 (42)</td>
<td>15 (38)</td>
<td>30 (40)</td>
</tr>
<tr>
<td>pM (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pM0</td>
<td>35 (97)</td>
<td>35 (90)</td>
<td>70 (93)</td>
</tr>
<tr>
<td>pM1</td>
<td>1 (3)</td>
<td>4 (10)</td>
<td>5 (7)</td>
</tr>
<tr>
<td>Pathologic stage (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I/II</td>
<td>20 (56)</td>
<td>24 (62)</td>
<td>44 (59)</td>
</tr>
<tr>
<td>III/IV</td>
<td>16 (44)</td>
<td>15 (38)</td>
<td>31 (41)</td>
</tr>
<tr>
<td>cT (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cT1-2</td>
<td>10 (34)</td>
<td>15 (41)</td>
<td>25 (38)</td>
</tr>
<tr>
<td>cT3-4</td>
<td>19 (66)</td>
<td>22 (59)</td>
<td>41 (62)</td>
</tr>
<tr>
<td>cN (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cN0</td>
<td>11 (41)</td>
<td>11 (31)</td>
<td>22 (35)</td>
</tr>
<tr>
<td>cN1-3</td>
<td>25 (59)</td>
<td>25 (69)</td>
<td>41 (65)</td>
</tr>
<tr>
<td>cM (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cM0</td>
<td>24 (96)</td>
<td>31 (97)</td>
<td>55 (96)</td>
</tr>
<tr>
<td>cM1</td>
<td>1 (4)</td>
<td>1 (3)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Clinical stage (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I/II</td>
<td>10 (45)</td>
<td>11 (42)</td>
<td>21 (44)</td>
</tr>
<tr>
<td>III/IV</td>
<td>12 (55)</td>
<td>15 (58)</td>
<td>27 (56)</td>
</tr>
<tr>
<td>Podoplanin expression (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>9 (25)</td>
<td>23 (59)</td>
<td>32 (43)</td>
</tr>
<tr>
<td>Low</td>
<td>27 (75)</td>
<td>16 (41)</td>
<td>43 (57)</td>
</tr>
<tr>
<td>p-4EBP1 expression (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>17 (47)</td>
<td>20 (51)</td>
<td>37 (49)</td>
</tr>
<tr>
<td>Low</td>
<td>19 (53)</td>
<td>19 (49)</td>
<td>38 (51)</td>
</tr>
</tbody>
</table>

P < 0.05. SD: standard deviation; CCRT: concurrent chemoradiotherapy. Some cases were excluded due to incomplete pre-treatment clinical staging.

The PI3K/AKT/mTOR signaling pathway is important in regulating essential cellular function, pN, pM, pathologic stage, cT, cN, cM or clinical stage.

Discussion

Our study showed for the first time that p-mTOR expression correlates with podoplanin expression in esophageal SCC. We also found an association between p-mTOR expression and high tumor grade, similar to a previous study on Dutch patients of esophageal SCC [39].

Correlation of p-mTOR expression with podoplanin and p-4EBP1

The H-scores of p-mTOR immunostaining grouped by podoplanin or p-4EBP1 expression were shown in Figure 3. The H-scores of podoplanin-high tumors were significantly higher than those of podoplanin-low tumors (P = 0.0031), whereas p-4EBP1 expression had no significant influence on H-scores of p-mTOR (P = 0.34). Using the median H-score as cutoff, high p-mTOR expression was also significantly associated with high podoplanin expression (P = 0.0030; Table 1), whereas p-mTOR expression was not correlated with p-4EBP1 expression (P = 0.73; Table 1). Examples of tumors with concordant (both high or both low) expression of p-mTOR and podoplanin were shown in Figure 4.
p-mTOR in esophageal cancer

Dysregulation of this pathway is also known to play important roles in carcinogenesis and tumor progression. However, the influence of p-mTOR expression on survival of esophageal SCC patients remains controversial. In a Japanese study, high expression of p-mTOR correlated with short survival in esophageal SCC patients [10]. In a Korean study, the ratio of p-mTOR/total mTOR was associated with survival.

Figure 3. The H-scores of p-mTOR immunostaining were grouped by podoplanin or p-4EBP1 expression. High p-mTOR expression was significantly associated with high podoplanin expression (P = 0.0031), whereas no association between p-mTOR and p-4EBP1 expression was observed.

Figure 4. A tumor showed high p-mTOR expression (A) and high podoplanin expression (B). Another tumor showed low p-mTOR expression (C) and low podoplanin expression (D). Lymphatic endothelial cells (arrows) served as internal positive control for podoplanin immunostaining.
p-mTOR in esophageal cancer

with poor prognosis, but the p-mTOR expression per se had no significant influence on patient survival [11]. In another Japanese study, high p-AKT expression correlated with short survival, but p-mTOR expression had no prognostic significance [12]. We found no significant influence of p-mTOR expression on survival in our cohort of esophageal SCC patients. Of note, a previous study on Dutch patients showed that p-mTOR expression correlated with higher grade tumor [39]. We also found a significant correlation between high p-mTOR expression and high tumor grade (P = 0.0014; Table 1).

The signals of PI3K/AKT/mTOR pathway and mitogen-activated protein kinase (MAPK) pathway converge on 4EBP1, which drives the downstream signals of cellular proliferation [13]. Previously, we found that high p-4EBP1 expression was an independent adverse prognostic factor in esophageal SCC, especially in patients with relatively early stage disease [14, 15]. In the present study, the lack of significant association of p-mTOR expression with p-4EBP1 expression (Figure 3; Table 1) and patient survival (Figure 2) was most likely due to the influence of signals from the MAPK pathway.

Podoplanin is a type 1 transmembrane mucin-like glycoprotein which was originally named due to its expression in renal podocytes of rats [40]. It is variously expressed in a variety of human tumors, including SCC of different organs. Podoplanin expression in cancer cells has been found to play multiple roles, most importantly lymphangiogenesis and lymph node metastasis [30]. There is also growing evidence that podoplanin is also involved in carcinogenesis, cell motility and cell invasiveness [27, 31, 32]. Since podoplanin is an endogenous ligand of C-type lectin-like receptor-2 (CLEC-2), a signaling receptor expressed on the surface of platelets [41], expression of podoplanin can promote platelet aggregation and hematogenous metastasis [33]. We previously found that high podoplanin expression correlates with clinical nodal metastasis and poor prognosis in esophageal SCC [23, 34]. However, the regulatory mechanism of podoplanin expression in esophageal SCC remains largely unknown.

In a mouse model of skin carcinogenesis, PDPN (podoplanin) was found to be a direct target gene of fos, a member of AP-1 family [32]. In addition, podoplanin expression in osteosarcoma was found to be regulated by AP-1 [42]. Podoplanin is also variably expressed in astrocytic tumors of the brain, and the frequency of expression increases along with the tumor grade, suggesting a role of podoplanin in malignant progression [43]. Podoplanin expression was also found to correlate with poor prognosis in glioblastoma, a high grade glial tumor with the highest frequency of podoplanin expression [44]. Recently, it has been found that podoplanin expression in astrocytic tumors is controlled by a PI3K/AKT/AP-1 pathway [37]. Since mTOR is activated by a PI3K/AKT/mTOR pathway, the association of podoplanin and p-mTOR expression in our study could be due to a common upstream pathway PI3K/AKT. Further study is needed to clarify the exact regulatory mechanism of podoplanin expression in esophageal SCC.

The PI3K/AKT/mTOR signaling pathway has long been considered as a therapeutic target. Multiple clinical trials targeting different parts of this pathway are ongoing for oral SCC [45], which is similar to esophageal SCC in tumor biology. Recently, inhibition of mTOR in esophageal SCC cells was found to increase the sensitivity to the chemotherapeutic agent cisplatin [46, 47]. Podoplanin is also a potential therapeutic target. An anti-podoplanin antibody NZ-1 has been found to inhibit podoplanin-induced platelet aggregation and pulmonary metastasis of podoplanin-overexpressing CHO cells in nude mice [48]. Since we found an association between p-mTOR and podoplanin expression, further preclinical and clinical studies are needed to clarify the possible benefit of combined targeted therapy.

In conclusion, our study showed for the first time that p-mTOR expression correlates with podoplanin expression in esophageal SCC. We also found an association between p-mTOR expression and high tumor grade. The correlation between p-mTOR and podoplanin expression could be due to a common upstream pathway PI3K/AKT. Since both mTOR and podoplanin are potential therapeutic targets, the possible benefit of combined targeted therapy warrants further investigation.

Acknowledgements

This work was supported by grants from the Ministry of Education, Taiwan, ROC (EMRPD-
p-mTOR in esophageal cancer

1E1391) and the Chang Gung Medical Research Program (CMRP3E0341 and CMRPD1C0041).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Chuen Hsueh, Department of Pathology, Chang Gung Memorial Hospital, 5 Fu-Hsing Street, Kwei-Shan, Taoyuan 333, Taiwan. Tel: + 886-3-3281200 Ext. 2741; Fax: + 886-3-3280147; E-mail: ch9211@adm.cgmh.org.tw

References

[20] Jokinen CH, Dadras SS, Goldblum JR, van de Rijn M, West RB and Rubin BP. Diagnostic implications of podoplanin expression in periph-


p-mTOR in esophageal cancer


